Medicare Enrolled

Dr. Robert Berryman, M.D.

Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
3410 WORTH ST STE 300, Dallas, TX 75246
2143701513
In practice since 2006 (19 years)
NPI: 1871535823 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Berryman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Berryman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Berryman

Dr. Robert Berryman is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Berryman performed 104,583 Medicare services across 2,896 unique beneficiaries.

Between the years covered by Open Payments, Dr. Berryman received a total of $162,583 from 49 pharmaceutical and/or device companies across 330 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Berryman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 10% volume in TX $162,583 industry payments

Medicare Practice Summary

Medicare Utilization ↗
104,583
Medicare services
Top 10% in TX for medical oncology
2,896
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,504 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Immune globulin infusion (Octagam) 31,800 $33 $234
Filgrastim injection (Nivestym) for white blood cells 27,102 $0 $2
Injection, daratumumab, 10 mg 23,240 $46 $167
Dexamethasone injection (steroid) 3,878 $0 $1
Comprehensive metabolic blood panel 1,812 $10 $64
Measurement of immunoglobulin light chains 1,801 $17 $60
Lactate dehydrogenase (enzyme) level 1,772 $6 $31
Magnesium level test 1,752 $7 $29
Complete blood count (CBC) with differential 1,477 $8 $36
Blood draw (venipuncture) 1,132 $8 $20
Office visit, established patient (30-39 min) 992 $94 $368
Injection, granisetron hydrochloride, 100 mcg 800 $0 $24
Injection of additional new drug or substance into vein 619 $12 $108
Hospital follow-up visit, high complexity 619 $93 $357
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour 523 $16 $100
Flow cytometry, additional marker 502 $19 $180
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 449 $22 $157
Injection, diphenhydramine hcl, up to 50 mg 409 $1 $7
Administration of chemotherapy into vein, 1 hour or less 393 $101 $707
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 378 $50 $313
Microscopic examination for white blood cells with manual cell count 348 $4 $22
Complete blood count (CBC), automated 346 $6 $34
Gammaglobulin (immune system protein) measurement, immunoglobulin subclasses 340 $8 $236
Drug injection, under skin or into muscle 277 $11 $96
Injection, methylprednisolone sodium succinate, up to 40 mg 208 $3 $14
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle 181 $58 $211
Infusion, normal saline solution , 1000 cc 111 $2 $19
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries 109 $89 $657
Tacrolimus level 105 $13 $101
Immunoglobulin level test 99 $9 $56
Injection, zoledronic acid, 1 mg 92 $7 $431
Nuclear medicine study whole body with ct scan 79 $1,180 $4,929
Infusion into a vein for hydration, each additional hour 77 $10 $75
Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services 76 $69 $70
Administration of vaccine, each additional vaccine 60 $12 $58
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion 57 $14 $94
Administration of chemotherapy into vein, each additional hour 56 $21 $161
Ferritin level test (iron stores) 42 $13 $60
Infusion, normal saline solution, sterile (500 ml = 1 unit) 37 $1 $19
Infusion into a vein for hydration, 31-60 minutes 32 $26 $256
Nuclear medicine study from skull base to mid-thigh with ct scan 30 $1,142 $4,802
PSA test (prostate cancer screening) 28 $18 $94
Pneumococcal vaccine, 13-valent 27 $253 $570
Hepatitis b vaccine, adult dosage (3 dose schedule) 27 $69 $165
Unclassified drugs 27 $16 $53
Administration of vaccine 25 $16 $58
Initial hospital admission, high complexity 25 $130 $694
Flu vaccine administration 23 $31 $58
Pneumonia vaccine administration 23 $31 $58
Administration of hepatitis b vaccine 23 $31 $58
Flow cytometry technique for dna or cell analysis, first marker 20 $60 $298
Injection of drug or substance into vein 20 $30 $247
Office visit, established patient, complex (40-54 min) 19 $129 $496
Biopsy and aspiration of bone marrow sample for diagnosis 18 $140 $523
Iron level test 18 $6 $27
Iron binding capacity test 17 $8 $35
Flu vaccine, quadrivalent 16 $76 $171
Hospital discharge management, 30+ min 15 $90 $368
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
32.0% high complexity
54.9% medium
13.1% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$162,583
Total received (2018-2024)
Avg $23,226/year across 7 years
Top 9% in TX for medical oncology
49
Companies
330
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$149,861 (92.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$7,262 (4.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,460 (3.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$17,637
2023
$5,964
2022
$35,442
2021
$28,140
2020
$11,635
2019
$32,145
2018
$31,622

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Karyopharm Therapeutics Inc.
$47,949
Takeda Pharmaceuticals U.S.A., Inc.
$40,647
GlaxoSmithKline, LLC.
$25,642
Amgen Inc.
$17,251
Celgene Corporation
$10,270
GENZYME CORPORATION
$5,325
E.R. Squibb & Sons, L.L.C.
$3,368
Genmab U.S., Inc.
$3,165
ABBVIE INC.
$2,668
Janssen Biotech, Inc.
$1,503
Astellas Pharma US Inc
$652
Incyte Corporation
$326
JAZZ PHARMACEUTICALS INC.
$315
ADC Therapeutics America, Inc.
$299
SANOFI-AVENTIS U.S. LLC
$267
Alexion Pharmaceuticals, Inc.
$247
Seagen Inc.
$209
PFIZER INC.
$200
Adaptive Biotechnologies Corporation
$188
Legend Biotech USA Inc.
$183
Pharmacyclics LLC, An AbbVie Company
$166
Rigel Pharmaceuticals, Inc.
$159
Merck Sharp & Dohme LLC
$158
AstraZeneca Pharmaceuticals LP
$156
Seattle Genetics, Inc.
$147
Janssen Scientific Affairs, LLC
$126
Daiichi Sankyo Inc.
$109
AbbVie Inc.
$100
Novartis Pharmaceuticals Corporation
$97
Jazz Pharmaceuticals Inc.
$80
SOBI, INC
$80
RECORDATI_RARE_DISEASES_INC.
$62
Genentech USA, Inc.
$61
MorphoSys, US Inc.
$47
CTI BioPharma Corp.
$41
Kyowa Kirin, Inc.
$39
Menarini Silicon Biosystems, Inc.
$38
Kite Pharma, Inc.
$33
Sobi, Inc
$28
Epizyme, Inc.,
$24
MENARINI SILICON BIOSYSTEMS, INC.
$22
INSYS Therapeutics Inc
$20
Lilly USA, LLC
$18
Agios Pharmaceuticals, Inc.
$18
Acrotech Biopharma Inc.
$18
EUSA Pharma (US) LLC
$17
Blueprint Medicines Corporation
$16
Merck Sharp & Dohme Corporation
$13
Verastem, Inc.
$11
Top 3 companies account for 70.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BELEODAQ · BLENREP · BOSULIF · Blincyto · CABLIVI · CALQUENCE · CARVYKTI · CRESEMBA · Cellsearch · Columvi · Copiktra · Cresemba · DARZALEX · DEFITELIO · DIFICID · DOPTELET · Doptelet · ELITEK · EMPLICITI · ENJAYMO · EPKINLY · Epkinly · Fabhalta · ICLUSIG · IMBRUVICA · Imbruvica · JAKAFI · JAYPIRCA · Kyprolis · LIVTENCITY · Lunsumio · MONJUVI · NINLARO · OJJAARA · PREVYMIS · PROMACTA · Polivy · Pomalyst · Poteligeo · REBLOZYL · REZUROCK · Revlimid · Rezlidhia · SARCLISA · SCEMBLIX · SHINGRIX · SYLVANT · SYNDROS · Sylvant · TAZVERIK · TECVAYLI · Tavalisse · ULTOMIRIS · VELCADE · VENCLEXTA · VONJO · VYXEOS · Vanflyta · Vonjo · XOSPATA · XPOVIO · Xospata · Yescarta · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 9% for medical oncology in TX.

Equivalent to $155 per 100 Medicare services performed
Looking for a medical oncology specialist in Dallas?
Compare medical oncologists in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
90
Per 100K population
3.5
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Berryman is a mixed practice specialist, with above-average Medicare volume (top 10% in TX), with speaking/promotional industry engagement in the top 9% of TX peers, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Berryman experienced with immune globulin infusion (octagam)?
Based on Medicare claims data, Dr. Berryman performed 31,800 immune globulin infusion (octagam) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Berryman receive payments from pharmaceutical companies?
Yes. Dr. Berryman received a total of $162,583 from 49 companies across 330 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Berryman's costs compare to other medical oncologists in Dallas?
Dr. Berryman's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Berryman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →